Kurita, Y.; Kobayashi, N.; Hara, K.; Mizuno, N.; Kuwahara, T.; Okuno, N.; Haba, S.; Tokuhisa, M.; Hasegawa, S.; Kubota, K.;
et al. Clinical Outcomes of Everolimus Rechallenge in Patients with Pancreatic Neuroendocrine Neoplasms with No Other Treatment Options. Cancers 2022, 14, 5669.
https://doi.org/10.3390/cancers14225669
AMA Style
Kurita Y, Kobayashi N, Hara K, Mizuno N, Kuwahara T, Okuno N, Haba S, Tokuhisa M, Hasegawa S, Kubota K,
et al. Clinical Outcomes of Everolimus Rechallenge in Patients with Pancreatic Neuroendocrine Neoplasms with No Other Treatment Options. Cancers. 2022; 14(22):5669.
https://doi.org/10.3390/cancers14225669
Chicago/Turabian Style
Kurita, Yusuke, Noritoshi Kobayashi, Kazuo Hara, Nobumasa Mizuno, Takamichi Kuwahara, Nozomi Okuno, Shin Haba, Motohiko Tokuhisa, Sho Hasegawa, Kensuke Kubota,
and et al. 2022. "Clinical Outcomes of Everolimus Rechallenge in Patients with Pancreatic Neuroendocrine Neoplasms with No Other Treatment Options" Cancers 14, no. 22: 5669.
https://doi.org/10.3390/cancers14225669
APA Style
Kurita, Y., Kobayashi, N., Hara, K., Mizuno, N., Kuwahara, T., Okuno, N., Haba, S., Tokuhisa, M., Hasegawa, S., Kubota, K., Nakajima, A., & Ichikawa, Y.
(2022). Clinical Outcomes of Everolimus Rechallenge in Patients with Pancreatic Neuroendocrine Neoplasms with No Other Treatment Options. Cancers, 14(22), 5669.
https://doi.org/10.3390/cancers14225669